Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

According to a doctor, other factors, such as exposure to contaminated needles, could also lead to HIV infections.

PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, ...

Having expanded access to quantitative hemoglobin variant testing in 40 countries, Hemex is now also setting its sights on the US and Europe.

Agios Pharmaceuticals said a key European regulatory committee has recommended expanded approval of its Pyrukynd anemia drug for certain people with the inherited blood disorder thalassemia. Agios on ...

About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...

Introduction β-Thalassemia is defined by a reduced or complete absence of β-globin chain synthesis in hemoglobin, leading to hemolytic anemia. Heterozygous β-thalassemia, also known as β-thalassemia ...

Severe malaria is associated with impaired nitric oxide (NO) synthase (NOS)–dependent vasodilation, and reversal of this deficit improves survival in murine models. Malaria might have selected for ...

Study Rundown: Non-transfusion-dependent (NTD) α- and β-thalassemia can cause chronic anemia, complications, and reduced quality of life. No oral disease-modifying therapies are currently approved for ...

Abstract: Iron deficiency anemia (IDA) and thalassemia (THL) are common hematological disorders that necessitate efficient and accurate screening for early diagnosis. Traditional blood smear analysis ...

Disclosures: Has received honoraria, advisory boards, research funding from AbbVie, Alexion, BeiGene, BMS, Celgene, Fibrogen, Forma, Janssen, Novartis, Taiho ...